JPMorgan Downgrades Accelerate Diagnostics (AXDX) to Underweight

JPMorgan analyst Tycho Peterson downgraded Accelerate Diagnostics (NASDAQ: AXDX) from Neutral to Underweight with a price target of $16.00.

• Steps aside following disappointing results released from highly-anticipated Mayo/UCLA study.
• Believes "ambitious" guidance for FY generates a significant burden and risk on the NT outlook.
• Sees better risk/reward offering elsewhere in coverage universe.

For an analyst ratings summary and ratings history on Accelerate Diagnostics click here. For more ratings news on Accelerate Diagnostics click here.

Shares of Accelerate Diagnostics closed at $20.64 yesterday.

You May Also Be Interested In

• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$231 at Bernstein SocGen
• Rackspace Technology Inc. (RXT) PT Raised to $5.50 at UBS
• Gartner (IT) PT Lowered to $164 at UBS on Q2 Outlook